Analyst Price Target is $7.83
▲ +217.14% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Akebia Therapeutics in the last 3 months. The average price target is $7.83, with a high forecast of $18.00 and a low forecast of $3.00. The average price target represents a 217.14% upside from the last price of $2.47.
Current Consensus is
The current consensus among 7 investment analysts is to buy stock in Akebia Therapeutics. This rating has held steady since February 2021, when it changed from a Hold consensus rating.
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.